Artwork

Kandungan disediakan oleh Clinical Care Options, LLC and Clinical Care Options. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Clinical Care Options, LLC and Clinical Care Options atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.
Player FM - Aplikasi Podcast
Pergi ke luar talian dengan aplikasi Player FM !

Congress to Clinic: Expert Takeaways on Emerging Data for MPNs

28:35
 
Kongsi
 

Manage episode 428574032 series 3256997
Kandungan disediakan oleh Clinical Care Options, LLC and Clinical Care Options. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Clinical Care Options, LLC and Clinical Care Options atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including:

  • Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the MOMENTUM trial
  • Efficacy of pacritinib in patients with MF who have both thrombocytopenia and anemia
  • Updated safety and efficacy data from the phase III MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor–naive MF
  • Impact of spleen volume on post-allogenic hematopoietic transplant outcomes in patients with MF: utility of 3D volumetrics in splenomegaly
  • Progression to MF in patients with essential thrombocythemia: an analysis from the prospective MOST study
  • JAK2V617F molecular response correlates with event-free survival in a patient population with early polycythemia vera
  • Phase III TRANSFORM-1 study: efficacy and safety of navitoclax combined with ruxolitinib vs ruxolitinib plus placebo in patients with untreated MF
  • Patient characteristics, treatment patterns, and health outcomes in a real-world population of patients with MF treated with fedratinib

Program faculty:

Brady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Resources:
To download the slides associated with this podcast discussion, please visit the program page.

  continue reading

181 episod

Artwork
iconKongsi
 
Manage episode 428574032 series 3256997
Kandungan disediakan oleh Clinical Care Options, LLC and Clinical Care Options. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Clinical Care Options, LLC and Clinical Care Options atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including:

  • Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the MOMENTUM trial
  • Efficacy of pacritinib in patients with MF who have both thrombocytopenia and anemia
  • Updated safety and efficacy data from the phase III MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor–naive MF
  • Impact of spleen volume on post-allogenic hematopoietic transplant outcomes in patients with MF: utility of 3D volumetrics in splenomegaly
  • Progression to MF in patients with essential thrombocythemia: an analysis from the prospective MOST study
  • JAK2V617F molecular response correlates with event-free survival in a patient population with early polycythemia vera
  • Phase III TRANSFORM-1 study: efficacy and safety of navitoclax combined with ruxolitinib vs ruxolitinib plus placebo in patients with untreated MF
  • Patient characteristics, treatment patterns, and health outcomes in a real-world population of patients with MF treated with fedratinib

Program faculty:

Brady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Resources:
To download the slides associated with this podcast discussion, please visit the program page.

  continue reading

181 episod

Semua episod

×
 
Loading …

Selamat datang ke Player FM

Player FM mengimbas laman-laman web bagi podcast berkualiti tinggi untuk anda nikmati sekarang. Ia merupakan aplikasi podcast terbaik dan berfungsi untuk Android, iPhone, dan web. Daftar untuk melaraskan langganan merentasi peranti.

 

Panduan Rujukan Pantas

Podcast Teratas